These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Sevoflurane Versus Desflurane on the Incidence of Postreperfusion Syndrome During Living Donor Liver Transplantation: A Randomized Controlled Trial.
    Author: Lee J, Yoo YJ, Lee JM, Park YJ, Ryu HG.
    Journal: Transplantation; 2016 Mar; 100(3):600-6. PubMed ID: 26335917.
    Abstract:
    BACKGROUND: Various interventions to reduce postreperfusion syndrome during liver transplantation have been explored, but the effect of volatile anesthetics used during liver transplantation on the incidence of postreperfusion syndrome has not been evaluated. A randomized controlled trial was performed to compare the incidence of postreperfusion syndrome between 2 commonly used volatile anesthetics, sevoflurane and desflurane. METHODS: Sixty-two adult liver recipients scheduled for living-donor liver transplantation were randomized to receive either sevoflurane or desflurane for general anesthesia. The incidence of postreperfusion syndrome, use of vasoactive drugs, and postoperative course were compared. The risk factors associated with postreperfusion syndrome were also analyzed. RESULTS: There was significantly less postreperfusion syndrome in the sevoflurane group compared to the desflurane group (38.7% vs 77.4%, P = 0.004) and less epinephrine was required in the sevoflurane group than the desflurane group (19.4% vs 45.2%, P = 0.030). Postoperative intensive care unit and hospital length of stay and postoperative course were similar between the groups. Multivariate analysis identified desflurane (compared to sevoflurane) as the only risk factor (odds ratio 7.314, P = 0.001) for reperfusion syndrome. CONCLUSIONS: When using volatile anesthetics for elective living donor liver transplantation, sevoflurane seems to be a better option than desflurane for reducing the incidence of postreperfusion syndrome.
    [Abstract] [Full Text] [Related] [New Search]